home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

58.70 +3.55 (+6.45%)

Streaming Delayed Price Updated: 10:38 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

34 35 Next >

Where Will Editas Medicine Be in 1 Year? ↗

November 20, 2022

The company could continue lagging the market for a while.

Via The Motley Fool

2 Growth Stocks That Could Double in 2023 ↗

November 17, 2022

Both are lagging the market this year.

Via The Motley Fool

Crispr Therapeutics Stock: Bull vs. Bear ↗

November 15, 2022

Crispr shares have fallen about 20% so far this year.

Via The Motley Fool

5 Top Stocks to Buy Before 2023 ↗

November 15, 2022

These stocks have what it takes to win over time.

Via The Motley Fool

Vertex Pharmaceuticals: Buy at the High? ↗

November 14, 2022

Vertex is submitting a potential blockbuster to regulators this month.

Via The Motley Fool

Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade ↗

November 12, 2022

These top stocks could be wise additions to a well-rounded investment portfolio.

Via The Motley Fool

Why Shares of CRISPR Therapeutics Dropped 19.9% in October ↗

November 07, 2022

Several factors weighed on the gene-editing biotech stocks last month.

Via The Motley Fool

Where CRISPR Therapeutics Stands With Analysts ↗

November 02, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

Via Benzinga

3 Top Healthcare Stocks Defying the Bear Market ↗

November 10, 2022

These healthcare companies haven't been slowed by macroeconomic conditions.

Via The Motley Fool

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today ↗

November 09, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a...

Via Benzinga

3 Healthcare Stocks That Could Go Parabolic ↗

November 09, 2022

These beaten-down stocks are ready for a rebound.

Via The Motley Fool

Got $1,000? 2 Smart Stocks to Consider Buying Right Now ↗

November 06, 2022

Don't overlook these major healthcare names on your next stock-buying spree.

Via The Motley Fool

2 Biotech Stocks That Could Make You Richer ↗

November 04, 2022

Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.

Via The Motley Fool

3 Top Healthcare Stocks to Buy for November ↗

November 04, 2022

Catalysts lie ahead for these promising stocks.

Via The Motley Fool

What 8 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

November 02, 2022

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for CRISPR Therapeutics ↗

November 02, 2022

Over the past 3 months, 8 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Better Buy: CRISPR Therapeutics vs. Bluebird Bio ↗

October 27, 2022

These two companies have performed almost equally poorly on the stock market in the past year.

Via The Motley Fool

2 Monster Stocks to Buy Without Any Hesitation ↗

October 26, 2022

These stocks are crushing the bear market.

Via The Motley Fool

Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

October 24, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.48% on an annualized basis producing an average annual return of 21.37%. Currently, CRISPR Therapeutics has a...

Via Benzinga

S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength ↗

October 22, 2022

Vertex and LNG play Cheniere Energy are setting up bullishly.

Via Investor's Business Daily

The Top 5 Stocks Cathie Wood Bought and Sold This Week ↗

October 21, 2022

Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager.

Via InvestorPlace

2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years ↗

October 21, 2022

They're both using unique and highly efficient approaches to developing and deploying their medicines.

Via The Motley Fool

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

2 Under-the-Radar Biotech Stocks to Buy in 2022 ↗

October 19, 2022

These two drugmakers are growing in prominence.

Via The Motley Fool

3 Cathie Wood Stocks to Buy and Hold for 10 Years ↗

October 19, 2022

The risks are formidable, but the chances of a massive gain are too much to pass up.

Via The Motley Fool

2 Top Healthcare Stocks to Buy for the Long Haul ↗

October 18, 2022

These biotech companies have a long ramp of revenue growth ahead.

Via The Motley Fool

My Best Stocks to Buy Now and Hold Forever ↗

October 14, 2022

These are ideal "forever" stocks.

Via The Motley Fool

Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold ↗

October 12, 2022

Vertex already generates billions in revenue -- but there may be more to come.

Via The Motley Fool

What 7 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

October 11, 2022

Analysts have provided the following ratings for CRISPR Therapeutics (NASDAQ:CRSP) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com